Company: PTHS
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001753926-25-000790
Chunk: 50

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 50
---
 Change

    Consultant
     
    $
    88,255

    $
    30,033

    $
                 58,222

    194
    %

    Lab
    Gas

    605

    —

                       605

    -
     %

    Lab
    Cell Storage

    15,428

    24,127

                 (8,699
    ) 

    (36
    )%

    Chemistry
    Manufacturing and Controls (“CMC”)

    82,170

    303,397

            (221,227
    ) 

    (73
    )%

    IP
    Services

    7,840

    109,049

            (101,209
    )

    (93
    )%

    Total
     
    $
    194,298

    $
    466,606

    $
            (272,308
    )

    (58
    )%

The
Company incurred less research and development expenses for the three months ended March 31, 2025, as compared to the corresponding
period in 2024 primarily as a result of a decrease in CMC fees of $221,227.

Professional
Fees

We
incurred professional expenses for the three months ended March 31, 2025 and 2024 of $549,630 and $679,815, respectively. For
the three months ended March 31, 2025, compared to the same period in 2024, this represented a decrease of $130,185, or 19%, as
a result of increased legal and accounting fees in 2024 due to the Company’s IPO.

Other
Expense

We
incurred other expense for the three months ended March 31, 2025 of $133,634 as compared to other expense for the three months
ended March 31, 2024 of $628,348. For the three months ended March 31, 2025, compared to the same period in 2024, this represented
a decrease of $494,714 or 79%. The other expense for the three months ended March 31, 2025 and 2024 was primarily the result of
decreased interest expense. The decrease in the interest expense was due to the remaining amortization of the debt discount on
the Company’s notes being